 At that time, CDER was more cautious about approving therapeutics and had a more adversarial relationship with the industry.The growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split.In its original form, CDER was composed of six offices